Pain in systemic inflammatory rheumatic diseases

Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

Contents lists available at ScienceDirect

Best Practice & Research Clinical Rheumatology journal homepage: www.elsevierhealth.com/berh

5

Pain in systemic inflammatory rheumatic diseases Fabiola Atzeni, MD, PhD a, *, Ignazio Francesco Masala b, Fausto Salaffi c, Manuela Di Franco d, Roberto Casale e, Piercarlo Sarzi-Puttini f a

IRCCS Galeazzi Orthopedic Institute, Milan, Italy  Hospital, Cagliari, Italy Orthopedic Unit, Santissima Trinita c  Politecnica delle Marche, Italy Chair of Rheumatology, Universita d Chair of Rheumatology, La Sapienza University, Rome, Italy e Department of Clinical Neurophysiology and Pain Rehabilitation Unit (RC), Foundation Salvatore Maugeri IRCCS, Montescano, Italy f Rheumatology Unit, L.Sacco University Hospital, Milan, Italy b

a b s t r a c t Keywords: Chronic pain Arthritides Inflammation Pharmacological therapy

The sometimes intense, persistent and disabling pain associated with rheumatoid arthritis (RA) and spondyloarthritis frequently has a multifactorial, simultaneously central and peripheral origin, and it may be due to currently active inflammation or joint damage and tissue destruction caused by a previous inflammatory condition. The symptoms of inflammatory pain symptoms can be partially relieved by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in central pain regulation mechanisms, as in the case of the chronic widespread pain (CWP) characterising fibromyalgia. The importance of distinguishing CWP from inflammatory pain is underlined by the fact that drugs such as tumour necrosis factor inhibitors are expensive, and direct costs are higher in patients with concomitant CWP than in those without. The management of pain requires a combination approach that includes pharmacological analgesia, and biological and non-biological treatments

* Corresponding author. Rheumatology Unit, L. Sacco University Hospital, Via G.B. Grassi 74, 20127 Milan, Italy. Tel.: þ39 02 39042489; fax: þ39 02 39043454. E-mail address: [email protected] (F. Atzeni). http://dx.doi.org/10.1016/j.berh.2015.04.016 1521-6942/© 2015 Elsevier Ltd. All rights reserved.

Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

2

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

because, although joint replacement surgery can significantly improve RA-related pain, it may only be available to patients with the most severe advanced disease. © 2015 Elsevier Ltd. All rights reserved.

Introduction The sometimes intense, persistent and disabling pain associated with rheumatoid arthritis (RA) and spondyloarthritis (SpA) [1e4] frequently has a multifactorial, simultaneously central and peripheral origin, and it may be due to currently active inflammation, or joint damage and tissue destruction caused by a previous inflammatory condition. Inflammatory pain symptoms can be partially relieved by non-steroidal anti-inflammatory drugs (NSAIDs) or biological and non-biological disease-modifying anti-rheumatic drugs (DMARDs), but many patients continue to experience moderate pain due to alterations in central pain regulation mechanisms, as in the case of the chronic widespread pain (CWP) characterising fibromyalgia (FM) [3,4]. Non-inflammatory pain may also confuse the assessment of disease activity, and so treatment should be aimed at relieving painful symptoms as well as combating inflammatory disease. The importance of distinguishing between central and inflammatory pain in patients with RA or SpA is underlined by the fact that these diseases are currently treated with expensive drugs such as tumour necrosis factor (TNF) inhibitors or other biological agents, and direct costs are higher in patients with concomitant CWP than in those without [3,4]. Optimal RA and SpA treatment must take into account symptoms such as CWP and the overall quality of life, and it requires a combination approach that includes pharmacological analgesia, and the use of biological and non-biological treatments because, although joint replacement surgery can significantly improve RA-related pain, it may only be available to patients with the most severe advanced disease [4]. Pain in RA and spondyloarthritis Rheumatoid arthritis RA is a common inflammatory joint disease that greatly affects the patients’ quality of life and working productivity, and the use of health-care resources [1,2]. Most RA patients consider pain their greatest problem and highest priority [4e7], and it may even cause more disability than structural joint damage [8,9]. Pain is often considered a marker of inflammation, but the intensity of pain is only weakly correlated with measures of peripheral inflammation [10,11]; however, it is associated with disease activity, and it is known that radiographic changes may lead to future pain [12e15]. It is becoming increasingly possible to suppress the inflammation that causes pain, stiffness and progressive joint damage, and to ensure clinical remission [16], which, if rapidly achieved, improves long-term outcomes [17,18]. Clinical trials have shown that early intensive treatment with DMARDs and corticosteroids leads to better pain outcomes [19e22], especially when disease activity is regularly monitored: the level of pain tends to decrease if inflammatory disease is suppressed soon after RA is diagnosed, although it often does not completely disappear [23e26] and may subsequently return to its initial level. RA-related pain may occur spontaneously or be evoked when a joint is moved within its normal working range, and it may even be felt in apparently normal surrounding tissue. Further, referred pain syndromes have also been reported because the intensity of the symptom does not necessarily correlate with the severity of the underlying disease or the absence of disease exacerbations [27,28]. The pain may be worsened by damage to a joint caused by inflammatory disease or concomitant osteoarthritis (OA), and the prevalence of chronic, non-inflammatory pain syndromes such as FM is higher among patients with RA than in the general population [29,30]. Patients with inflammatory arthritis and FM are more likely to have more active disease and a poorer quality of life than those Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

3

without FM and, as pain also indirectly contributes to the psychological and social impact of RA, analgesia is important [1,2]. Inflammatory spondyloarthropathies Inflammatory spondyloarthropathies (SpAs) include ankylosing spondylitis (AS), reactive arthritis and arthritis/spondylitis associated with psoriasis (PsA) or inflammatory bowel disease (IBD) [31]. The first is a chronic inflammatory disease of the axial skeletal system that is mainly characterised by back pain, progressive spinal stiffness, enthesopathy, arthritis and peripheral extra-articular manifestations, and it generally causes functional incapacity [31,32]. It has a male/female ratio of 3e4:1, and it is more frequent and prevalent in young men [33]. The pain can be intense, persistent and disabling [1,28], and it is the main reason for seeking rheumatological care. It may be due to active inflammation or joint damage arising from previous inflammation and tissue destruction, but it is frequently multifactorial in origin and has both central and peripheral components [34]. Treatment with DMARDs and NSAIDs reduces the inflammatory pain symptoms [35], although the fact that many patients continue to experience moderate pain [36,37] suggests the existence of a non-inflammatory component with a different aetiology and/or alterations in central pain regulation mechanisms [38]. Many researchers now believe that CWP is a disease per se, and that its location may be less relevant than genetically determined sensitivity to pain; furthermore, pain transmission may be increased by neuroplastic changes in the central nervous system (CNS) [38e40]. The heightened sensitivity to pain may be associated with hyperalgesia (increased pain in response to normally painful stimuli) and/or allodynia (pain in response to normally non-painful stimuli), may be local or widespread, and may be triggered by an initial peripheral injury or inflammatory process [39,40], but the many other complex mechanisms involved include temporal summation (wind-up), long-term potentiation (LTP), heterosynaptic potentiation, dysfunctional descending pain inhibition and activation of the descending facilitatory pathway [41]. The mechanisms of pain Rheumatoid arthritis The causes of RA-related pain may be different in early and late disease stages, during and between inflammatory flares and between individuals. An inflamed synovium generates mediators such as prostaglandins and bradykinin, and pro-inflammatory cytokines such as TNF-a, interleukin-1 (IL-1), IL6 and nerve growth factor beta (NGF-b), which sensitise peripheral nerves, thus significantly contributing to pain generation and maintenance [42e45]. However, it is unlikely that the synovium is the only source of pain as sensory nerves are also located in joint capsules, ligaments, the outer regions of the menisci, subchondral bone, tendon sheaths and muscles [42], although articular cartilage and the inner two-thirds of the menisci are normally aneural and allow normal, pain-free weight bearing and joint movement. Synovitis is associated with alterations in neurotransmitters such as g-aminobutyric acid (GABA), substance P and calcitonin gene-related peptide (CGRP), and their receptors in the spinal cord [46,47], as well as the activation of the microglia and astrocytes inside the spinal cord to produce TNF-a, IL-1 and IL-6, which facilitate pain transmission [48,49]. Nociceptive transmission may also be further increased as a result of greater descending activation and reduced descending inhibition [50e52]. Finally, central sensitisation may be more widespread than the innervation of the inflamed joint and reduce pain thresholds in adjacent tissues [53]. Widespread reductions in pain pressure thresholds have been associated with moodiness and sleep disturbances [54,55], and cross-sectional surveys have found that about 8% of RA patients satisfy the FM classification criteria [56,57]. However, although these criteria may identify the subgroup of patients with the most abnormal pain processing, they may conceal the larger number of patients whose symptoms are due to similar pain mechanisms. Pain in RA may be further exacerbated by joint damage due to inflammatory disease or concomitant OA, particularly in the case of long-established disease. The structural changes associated with RA Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

4

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

(erosions and joint space narrowing) cause greater pain, but they may explain only 2% of pain intensity after adjusting for factors such as current disease activity [58]. Psychological factors also influence pain reporting [59,60], and depression has been associated with greater pain [61]. The experience of pain is therefore multifaceted, and it includes both sensory and emotional components, as is shown by the fact that pain can persist despite adequate control of inflammation [1,2]. Ankylosing spondylitis Studies have shown that widespread pain significantly increases AS disease activity [34], and growing evidence of an association between FM and SpA increases the need to distinguish their clinical features [62e65]. The main cause of diagnostic confusion relating to the 1990 ACR criteria [66] was the overlap between SpA-related enthesitis and FM-related tender points (TPs); the latter were therefore replaced by patient self-assessment in the 2010 ACR FM diagnostic criteria [30], but some confusion remains [67]. Although pain is a cornerstone of AS, it does not necessarily reflect increased inflammatory disease activity [34], and sometimes it seems to be more related to a mechanism of central pain sensitisation similar to that observed in FM [35]. However, it is difficult to assess widespread pain in AS patients because of the presence of enthesitis and tenosynovitis [31,32] and, as tendon insertion sites are located throughout the body, it is not always clear whether the pain is related to disease activity or reflects an associated pain syndrome. The mechanisms leading to the development of CWP in patients with inflammatory arthritis are still unclear, but a number of studies have shown that widespread pain conditions such as FM are highly prevalent in AS patients. The impact of CWP on disease activity indices in RA and SpA Rheumatoid arthritis The 28-joint Disease Activity Score (DAS28) is frequently used to assess joint inflammation in randomised controlled trials (RCTs) and guide treatment decisions in clinical practice. Furthermore, intensive targeted regimens require treatment escalation in patients with active disease, and some national guidelines (such as those of the UK) restrict the use of biological agents to patients with a high DAS28 score [68,69]. However, the relationship between DAS28 and inflammatory disease activity is confounded by other factors. Visual analogue scales (VAS) and tender joint counts (TJCs) increase with inflammation, and are both closely related with reported bodily pain [70], but they may also be increased by concomitant painful conditions such as OA, which usually affect the hand and knee joints included in the DAS28, or by changes in pain processing such as central sensitisation, which coincides with joint inflammation and may make the DAS28 more difficult to interpret [71,72]. Two recent studies have found that pain significantly affects patient assessments of RA disease activity; the first involved 7028 patients entered in the Quantitative Standard Monitoring of Patients with RA (QUEST-RA) database [73], and it showed that pain was the single most important determinant of patient global assessments; the second involved 646 RA patients starting methotrexate (MTX) treatment at an outpatient clinic, and it found that pain explained 75.6% of the variability of the patient global assessment scores [74]. Pain contributed less to physician global assessments (it was the fourth most important determinant), but the fact that it was one of the most significantly discordant variables between the patient and physician global assessments in both studies suggests that physicians should give it greater weight. Spondyloarthritis Disease activity indices are often used in patients with SpA [75,76], and there is a good correlation between self-reported indices (including the Bath Ankylosing Spondylitis Disease Activity Index, BASDAI) [77] and the presence of CWP or FM, which suggests that the CWP frequently reported by women with inflammatory rheumatic diseases may also be frequent in women with axial SpA. This can cause diagnostic delays and may also partially explain why women's self-reported functional limitations are worse than those of men at any given level of radiographic damage. However, women with Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

5

primary FM have much higher BASDAI scores than women with AS [78], and the BASDAI may not be such a good means of assessing inflammatory disease activity in SpA patients. Aloush et al. [79] studied 36 AS patients (18 males and 18 females), and they diagnosed FM in 50% of the women but none of the men. They also found that patients with concomitant diseases were more functionally impaired than those with only one disease, which led to higher BASDAI and Bath Ankylosing Spondylitis Functional Index (BASFI) scores. Another study of 71 AS patients (45.5% males and 54.5% females) found a 15% prevalence of FM, and these patients had significantly higher BASDAI, BASFI and Ankylosing Spondylitis Quality of Life (ASQoL) scores [80]. Finally, a cross-sectional Spanish study of 462 patients with definite AS found that the prevalence of FM was 4.11% in the population as a whole, but 10.83% among women [81]. It also found that the BASDAI, BASFI and total Bath AS Radiology Index (BASRI) were greatly influenced by the presence of FM, which was very likely in the patients with a BASDAI/BASRI ratio of 1.5 or a BASFI/BASRI ratio of 1.08. The conclusion drawn was that FM in patients with AS distorts measures of disease activity and functional damage, and that using BASDAI/BASRI and BASFI/BASRI ratios may help to avoid over-treatment [81]. The BASDAI is based on a subjective assessment of fatigue, stiffness and pain and, as these symptoms also characterise CWP conditions, it is difficult to establish disease activity and functional capacity in AS patients with concomitant FM [82]. In an attempt to overcome this drawback, a study of 547 patients entered in the Scotland and Ireland Registry for Ankylosing Spondylitis (SIRAS) [83] used fourview body manikins to obtain information concerning CWP not only on the basis of the 1990 ACR criteria for FM (ACR-CWP: i.e., chronic pain for >3 months in two contralateral body quadrants plus axial pain) but also on the basis of an alternative definition (aCWP) that required chronic pain in two contralateral body quadrants, but it excluded axial skeletal and/or buttock pain in order to avoid the potentially confounding effect of spinal disease. The results showed that the age- and gender-adjusted prevalence of aCWP among AS patients was almost three times higher than that in the general population, and it was related to both individual and clinical factors.. It is known that patients with inflammatory arthritides are more likely to develop CWP and report disability and a poor quality of life if their painful symptoms remain untreated [26], and it can be presumed that the same is true of patients with RA or AS.

Pharmacological management of RA and SpA-related pain Rheumatoid arthritis The 3e (evidence, expertise and exchange) initiative is a 17-country collaborative project that promotes evidence-based practice in rheumatology that has recently published recommendations concerning the pharmacological management of pain in patients with inflammatory arthritis [35], many of which are based on a series of Cochrane database systematic reviews published in 2011e2012. RA patients are often given NSAIDs to manage their pain, but they are not appropriate for long-term disease control [84,85]. Nevertheless, although it is recognised that the early use of DMARDs is very important [86], pain often drives patients to take analgesics from the start, and the European League Against Rheumatism (EULAR) recommends the use of NSAIDs for symptomatic patients with early arthritis once their gastrointestinal, renal and cardiovascular status has been carefully evaluated [87,88]. However, the use of analgesics is only indirectly evidence based because it is based on the findings of RCTs involving patients with other conditions, which may actually conceal some findings of their inefficacy in arthritis. For example, paracetamol is readily available but there is little RCT-based evidence supporting its use [89], and trials have often used it in combination with a different class of analgesic: furthermore, paracetamol is often used in combination products and this may mask cumulative paracetamol intake, which should not exceed 4 g in healthy adults. On the other hand, typical paracetamol-containing products include opioid combinations (codeine, tramadol, oxycodone, etc.) that may provide effective analgesia at lower opioid doses than single opioids [90], and it has been demonstrated that the fixed-dose combination of tramadol and paracetamol leads to synergistic benefits [91]. Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

6

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

However, one systematic review [91] of 11 randomised or quasi-randomised trials comparing opioids with placebo or an active analgesic concluded that the evidence in favour of the use of weak opioids such as codeine, dextropropoxyphene, pentazocine, tilidine and tramadol is itself weak and, in comparison with placebo, there was a 2.7 greater risk of study withdrawal due to frequent constipation, dizziness, nausea and vomiting in the opioid-treated patients. Furthermore, there is a risk of opioid-induced hyperalgesia leading to greater sensitivity to pain and increased clinical pain intensity, and so it is generally recommended to minimise long-term opioid prescriptions and, when opioids are necessary, to monitor their use regularly [92]. One Cochrane systematic review found that the evidence supporting the use of neuromodulators to treat RA-related pain was also weak [93], although it only considered four small randomised, placebocontrolled trials (two of nefopam, a centrally acting analgesic used in Europe but not in the USA; one of topical capsaicin; and one of oro-mucosal cannabis), and the authors concluded that topical capsaicin could be considered as adjuvant pain treatment [94]. Other possible adjuvant treatments recommended by the 3e initiative are gabapentin and pregabalin, although it should be remembered that these recommendations are mainly based on their efficacy in studies of pain in FM, a non-inflammatory condition of CWP [35]. The disease can be controlled by glucocorticosteroids and traditional DMARDs such as MTX in most patients [95], with biological therapies [96] being reserved for those with very advanced or severe disease. Both glucocorticosteroids and DMARDs reduce RA-related pain and, although the analgesic effects of the former may not last longer than 3 months [97], the early suppression of inflammatory disease activity not only reduces pain in the short term but avoids the development of worse pain 12 months after diagnosis. Finally, DMARD combinations may be more effective than monotherapy. However, it must be remembered that inflammation is only one factor contributing to the pain felt by many arthritic patients, and symptomatic relief is frequently incomplete even when reductions in swollen joint counts, acute-phase reactant levels and ultrasound findings of synovitis indicate inflammatory control. This and the often-slow action of DMARDs mean that alternative strategies are necessary. Appropriate analgesia can have a positive effect on disease activity scores by reducing joint tenderness and improving patient-reported general health, but it is necessary not to mistake this for the suppression of the underlying disease. Tricyclic antidepressants (TCAs such as amitriptyline, dothiepin and imipramine) inhibit serotonin and norepinephrine reuptake and neuronal sodium channels [98], but their non-serotoninergic properties account for differences in their individual antinociceptive effects. Clinical trials of the use of TCAs in RA patients have led to equivocal results: a Cochrane systematic review of eight RCTs comparing antidepressant therapy with placebo or an active intervention found insufficient evidence to recommend its use to treat RA-related pain [98], but the 3e recommendations include TCAs as a possible adjuvant treatment for patients with inflammatory arthritis [35], although it was specifically noted that this only applied to a subset of patients. Nevertheless, TCAs are significantly more pain relieving than placebo and it has been proposed that, like anticonvulsants, they can be considered ‘pain-modifying drugs’. The current stratification of analgesic treatment is based on potency or sequential trials, beginning with the least expensive low-risk treatments; individual treatment failures suggest that patients may benefit more if stratified care is based on a combined evaluation of inflammation, joint damage and central sensitisation, and that the multidimensional nature of RA and most other chronic pain indications requires a combined approach to analgesia. Non-pharmacological treatment of RA-related pain Because chronic pain acceptance, coping skills and self-efficacy contribute to the quality of life of RA patients, psychological interventions such as cognitive behavioural therapy (CBT) may also help [99e101]. A better understanding of pain mechanisms can limit catastrophic thoughts relating to pain, and combined psychological and pharmacological treatments can facilitate pain control. Cognitive therapy alone may be effective, and it does necessarily need to be combined with behavioural strategies [100,101]. RA patients with moderately active disease and restricted joint erosions may benefit from aerobic exercises and dynamic strength training. Short-term, land-based aerobic exercise alone Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

7

may improve aerobic capacity immediately after the intervention, but not muscle strength or functional ability, whereas combined short- and long-term, land-based aerobic and strength training may improve both. Exercise does not seem to increase pain or disease activity and, in addition to being safe, resistance exercise can lead to statistically significant and possibly clinically relevant improvements in most RA-related pain and disability outcomes [100]. Joint replacement Joint replacement surgery can give substantial relief to patients with severe, unremitting pain localised to a single joint [101,102]. The underlying reasons are still unknown, but they may include the physical protection of subchondral nerves or the prevention of synovitis originating in cartilage. However, although the routine use of total joint replacement surgery in clinical practice and the more recent development of biological therapies that suppress underlying inflammatory disease have improved the quality of life of large numbers of patients, both are associated with substantial healthcare expenditure [103]. Furthermore, 15% of the patients undergoing total knee replacement surgery continue to experience persistent and disabling pain, and up to 25% of those given anti-TNF agents because of presumed active RA actually receive no meaningful benefit [104]. In conclusion, both short- and long-term outcomes can be optimised by combining RA treatments targeting inflammatory mechanisms (which relieve pain by suppressing synovitis and may also reduce central sensitisation by modulating neuro-immune interactions in the CNS) with pharmacological and non-pharmacological therapies aimed at relieving RA-related pain. Spondyloarthritis The impact of CWP on the quality of life of AS patients can raise doubts at the time of diagnosis and when assessing responses to the treatments recommended by the evidence-based Assessment of Spondyloarthritis International Society (ASAS) and the EULAR: that is, NSAIDs because of the involvement of the spine, and classic DMARDs for peripheral manifestations. In the case of a lack of response to first-line therapy, patients are usually switched to an anti-TNF-a drug [105], but this can raise management difficulties because, as patients with a secondary pain syndrome complain of pain even when inflammation is effectively controlled, they may undergo unnecessary treatment changes or dose escalations. It is known that NSAIDs alone have no effect on CWP due to central sensitisation, and they are therefore unlikely to be effective in AS patients with CWP. Various studies have demonstrated that antiTNF agents act on the symptoms and signs of AS (including acute inflammatory pain), but no study has yet investigated their effects on CWP [106], the treatment of which is particularly challenging because its aetiology is still not clear and patients respond poorly to conventional treatments. Controlled studies have shown that tricyclic antidepressants such as amitriptyline; selective serotonin reuptake inhibitors such as fluoxetine; and dual serotonin and norepinephrine inhibitors such as venlafaxine, milnacipran and duloxetine may be useful in treating CWP in patients with FM, but only a small proportion respond to any of these treatments alone [107e109]. Summary The complex and multifactorial phenomenon of pain is a major component of many rheumatological conditions, and the result of physiological interactions between the central and peripheral nervous system signalling: acute pain is often primarily attributable to nociceptive inputs such as inflammation and/or peripheral structural damage, whereas chronic pain (usually defined as lasting 3 months) is more likely to be due to inputs from the CNS. These many different aspects can make it difficult for rheumatologists and other clinicians to diagnose the type of pain correctly and treat it appropriately. One still open question is the origin of CWP in patients with arthritis. It may or may not be due to a genetic and/or familial predisposition, psychological factors, inflammation or cytokines; to all of these; or to just one that reflects and affect the nociceptive system. The only thing that can be done at the Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

8

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

moment is to continue to look for joint abnormalities and central processing alterations in order to discover which come first, and then develop the most appropriate means of treating (and even preventing) arthritis-related CWP.

Practice points 1. Pain is a cornerstone of the definition of AS and RA, but it may be due to a mechanism related to central pain sensitisation (similar to that observed in FM) as well as inflammation. 2. Inflammatory pain symptoms can be reduced by NSAIDs and biological and non-biological DMARDs, but many patients continue to experience moderate pain due to alterations in central pain regulation mechanisms, as in the case of CWP. 3. It is important to identify the symptoms of CWP in order to be able to manage and treat patients with arthritides appropriately. 4. Optimal treatment needs to take into account symptoms such as CWP and the overall quality of life, and it requires various approaches that include pharmacological analgesia and biological and non-biological therapies. 5. Joint replacement surgery can significantly improve RA-related pain, but it may only be available to patients with the most severe, advanced disease.

Research agenda  To develop new laboratory and clinical indices for distinguishing CWP from inflammatory pain in rheumatic disease in order to reduce misdiagnoses  To evaluate the adequacy and appropriateness of measures for diagnosing primary and secondary pain  To determine whether new instrumental methods such as ultrasonography can distinguish CWP from other types of pain  To develop new recommendations for differentiating widespread pain in the context of rheumatic diseases  To promote future multicentre studies and registries of widespread pain in inflammatory rheumatic diseases in order to reduce the overestimated disease activity revealed by current scores

Disclosure of interests The authors declare that they have no conflicts of interest in relation to this article. References *[1] Kazis LE, Meenan RF, Anderson JJ. Pain in the rheumatic diseases. Investigation of a key health status component. Arthritis Rheum 1983;26:1017e22. [2] Atzeni F, Boccassini L, Di Franco M, et al. Chronic widespread in spondyloarthritis. Reumatismo 2014;66(1):28e32. [3] Sarzi-Puttini P, Salaffi F, Di Franco M, et al. (Italian Fibromyalgia Network). Pain in rheumatoid arthritis: a critical review. Reumatismo 2014;66:18e27. [4] Walsh DA, McWilliams DF. Pain in rheumatoid arthritis. Curr Pain Headache Rep 2012;16:509e17. *[5] Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep 2013;15:300. [6] Heiberg T, Kvien TK. Preferences for improved health examined in 1024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 2002;47:391e7.

Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

9

[7] Taylor P, Manger B, Alvaro-Gracia J, et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res 2010;38:1213e24. [8] Minnock P, FitzGerald O, Bresnihan B. Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status. Rheumatology 2003;42:995e1000. [9] Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22:1e12. [10] Khan NA, Spencer HJ, Abda E, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res 2012;64:206e14. *[11] Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in the perception of rheumatoid arthritis disease activity. Arthritis Rheum 2012;64:2814e23. [12] Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008;10:R106. [13] Odegard S, Finset A, Mowinckel P, et al. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2007;66:1195e201. [14] Sokka T, Kankainen A, Hannonen P. Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis Rheum 2000;43:386e9. [15] Sarzi-Puttini P, Fiorini T, Panni B, et al. Correlation of the score for subjective pain with physical disability, clinical, and radiographic scores in recent onset rheumatoid arthritis. BMC Musculoskelet Disord 2002;3:18. [16] McWilliams DF, Zhang W, Mansell JS, et al. Predictors of change in bodily pain in early rheumatoid arthritis: an inception cohort study. Arthritis Care Res (Hoboken) 2012;64:1505e13. [17] Schipper LG, Fransen J, den Broeder AA, Van Riel PL. Time to achieve remission determines time to be in remission. Arthritis Res Ther 2010;12:R97. [18] Finckh A, Choi HK, Wolfe F. Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 2006;65:1192e7. [19] Soubrier M, Lukas C, Sibilia J, et al. Disease activity score-driven therapy vs routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011;70:611e5. *[20] Atzeni F, Sarzi-Puttini P. Rheumatoid arthritis: why wait? Explaining delays in seeking therapy for early arthritis. Nat Rev Rheumatol 2012;8:190e1. [21] Andersson ML, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol 2013;40:1977e85. [22] van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007;56:2129e34. [23] Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatol 2007;34:1674e83. [24] Wiles NJ, Scott DG, Barrett EM, et al. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann Rheum Dis 2001;60:956e61. [25] Rupp I, Boshuizen HC, Roorda LD, et al. Course of patient-reported health outcomes in rheumatoid arthritis: comparison of longitudinal and cross-sectional approaches. J Rheumatol 2006;33:228e33. [26] Roche PA, Klestov AC, Heim HM. Description of stable pain in rheumatoid arthritis: a 6 year study. J Rheumatol 2003; 30:1733e8. [27] Gerecz-Simon EM, Tunks ER, Heale JA, et al. Measurement of pain threshold in patients with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and healthy controls. Clin Rheumatol 1989;8:467e74. *[28] Atzeni F, Cazzola M, Benucci M, et al. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol 2011;25:165e71. [29] Wolfe F. Fibromyalgianess. Arthritis Rheum 2009;61:715e6. [30] Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113e22. [31] Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med 2005;118:592e603. [32] Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61(Suppl. 3):iii8e18. [33] Dean LE, Jones GT, Macdonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014; 53(4):650e7. [34] Dhondt W, Willaeys T, Verbruggen LA, et al. Pain threshold in patients with rheumatoid arthritis and effect of manual oscillations. Scand J Rheumatol 1999;28:88e93. [35] Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology (Oxford) 2012;51:1416e25. [36] Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs e a systematic review and network meta-analysis. Health Qual Life Outcomes 2014;12:102. [37] Lee YC, Cui J, Lu B, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011;13:R83. [38] Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states e maybe it is all in their head. Best Pract Res Clin Rheumatol 2011;25:141e54. [39] Woolf CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 2004;74:2605e10. [40] Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009;31:206e19. [41] Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2010;152:S2e15. [42] Konttinen YT, Tiainen VM, Gomez-Barrena E, et al. Innervation of the joint and role of neuropeptides. Ann N Y Acad Sci 2006;1069:149e54.

Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

10

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11 [43] Schaible HG, Ebersberger A, Von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci 2002;966:343e54. [44] Raychaudhuri SP, Raychaudhuri SK, Atkuri KR, et al. Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum 2011;63:3243e52. [45] Schaible HG, von Banchet GS, Boettger MK, et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci 2010;1193:60e9. [46] Benemei S, Nicoletti P, Capone JG, Geppetti P. CGRP receptors in the control of pain and inflammation. Curr Opin Pharmacol 2009;9:9e14. [47] Brenn D, Richter F, Schaible HG. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum 2007;56:351e9. [48] Zhang L, Berta T, Xu ZZ, et al. TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain 2011;152:419e27. [49] Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002;82:981e1011. [50] Richter F, Natura G, Loser S, et al. Tumor necrosis factor causes persistent sensitization of joint nociceptors to mechanical stimuli in rats. Arthritis Rheum 2010;62:3806e14. [51] Bekkelund SI, Mellgren SI, Proven A, Husby G. Quantified neurological examination with emphasis on motor and sensory functions in patients with rheumatoid arthritis and controls. Br J Rheumatol 1996;35:1116e21. [52] Leffler AS, Kosek E, Lerndal T, et al. Somatosensory perception and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from rheumatoid arthritis. Eur J Pain 2002;6:161e76. [53] Huskisson EC, Hart FD. Pain threshold and arthritis. Br Med J 1972;4:193e5. [54] Covic T, Tyson G, Spencer D, Howe G. Depression in rheumatoid arthritis patients: demographic, clinical, and psychological predictors. J Psychosom Res 2006;60:469e76. [55] Drewes AM, Svendsen L, Taagholt SJ, et al. Sleep in rheumatoid arthritis: a comparison with healthy subjects and studies of sleep/wake interactions. Br J Rheumatol 1998;37:71e81. [56] Irwin MR, Olmstead R, Carrillo C, et al. Sleep loss exacerbates fatigue, depression, and pain in rheumatoid arthritis. Sleep 2012;35:537e43. [57] Nicassio PM, Ormseth SR, Kay M, et al. The contribution of pain and depression to self-reported sleep disturbance in patients with rheumatoid arthritis. Pain 2012;153:107e12. [58] Khanna D, Ranganath VK, Fitzgerald J, et al. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis Rheum 2005;52:2284e92. [59] Hagglund KJ, Haley WE, Reveille JD, Alarcon GS. Predicting individual differences in pain and functional impairment among patients with rheumatoid arthritis. Arthritis Rheum 1989;32:851e8. [60] Edwards RR, Cahalan C, Mensing G, et al. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol 2011;7:216e24. [61] Hewlett S, Sanderson T, May J, et al. “I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count e an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012;51:69e76. [62] Konno T. Differentiation of the clinical features of psoriatic arthritis and fibromyalgia. J Rheumatol 2012;39:11. [63] Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology 2003;42:263e7. [64] Salaffi F, Sarzi-Puttini P, Ciapetti A, Atzeni F. Clinimetric evaluations of patients with chronic widespread pain. Best Pract Res Clin Rheumatol 2011;25:249e70. [65] Salaffi F, Sarzi-Puttini P, Ciapetti A, Atzeni F. Assessment instruments for patients with fibromyalgia: properties, applications and interpretation. Clin Exp Rheumatol 2009;27(5 Suppl. 56):S92e105. [66] Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160e72. [67] Salaffi F, Sarzi-Puttini P. Old and new criteria for the classification and diagnosis of fibromyalgia: comparison and evaluation. Clin Exp Rheumatol 2012;30(6 Suppl. 74):3e9. [68] van der Heijde DM, van't Hof MA, van Riel PL, et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177e81. [69] Leeb BF, Andel I, Sautner J, et al. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford) 2004;43:1504e7. [70] Pollard LC, Kingsley GH, Choy EH, Scott DL. Fibromyalgic rheumatoid arthritis and disease assessment. Rheumatology (Oxford) 2010;49:924e8. [71] Dhir V, Lawrence A, Aggarwal A, Misra R. Fibromyalgia is common and adversely affects pain and fatigue perception in North Indian patients with rheumatoid arthritis. J Rheumatol 2009;36:2443e8. [72] Ranzolin A, Brenol JC, Bredemeier M, et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:794e800. [73] Sokka T, Toloza S, Cutolo M, et al., QUEST-RA Group. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009;11(1):R7. [74] Kiely P, Walsh D, Williams R, Young A. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity e the early RA network (ERAN). Rheumatology (Oxford) 2011;50:926e31. [75] Coates LC, Mumtaz A, Helliwell PS, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA) e report of the OMERACT 10 PsA special interest group. J Rheumatol 2011;38:1496e501. *[76] Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl. 2):ii1e44. [77] Slobodin G, Reyhan I, Avshovich N, et al. Recently diagnosed axial spondyloarthritis: gender differences and factors related to delay in diagnosis. Clin Rheumatol 2011;30:1075e80.

Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016

F. Atzeni et al. / Best Practice & Research Clinical Rheumatology xxx (2015) 1e11

11

[78] Heikkila S, Ronni S, Kautiainen HJ, Kauppi MJ. Functional impairment in spondyloarthropathy and fibromyalgia. J Rheumatol 2002;29:1415e9. [79] Aloush V, Ablin JN, Reitblat T, et al. Fibromyalgia in women with ankylosing spondylitis. Rheumatol Int 2007;27: 865e8. [80] Azevedo VF, Paiva Edos S, Felippe LR, Moreira RA. Occurrence of fibromyalgia in patients with ankylosing spondylitis. Rev Bras Reumatol 2010;50:646e50. var R, Carmona L, Zarco P, et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of [81] Almodo the measures of activity, function and radiological damage. Clin Exp Rheumatol 2010;28:S33e9. [82] Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994;21:2286e91. *[83] Atzeni F, Beasly M, Dean L, et al. Do patients with ankylosing spondylitis have an excess prevalence of chronic widespread pain? Results from the Scotland and Ireland Registry for Ankylosing Spondylitis (SIRAS) and the MUSICIAN study. Arthritis Rheum 2013 [abstract]. [84] di Munno O, Sarchi C. Effectiveness of tolmetin in rheumatoid arthritis: evaluation by means of a new method. Methods Find Exp Clin Pharmacol 1982;4:203e6. [85] Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol 2013;31(5):731e8. [86] Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347e56. [87] Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906e14.  R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with *[88] Smolen JS, Landewe synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964e75. [89] Wienecke T, Gotzsche PC. Paracetamol vs nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev 2004;1:CD003789. [90] Lee EY, Lee EB, Park BJ, et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial. Clin Ther 2006;28: 2052e60. [91] Whittle SL, Richards BL, Husni E, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev 2011;11:CD003113. [92] Zuccaro SM, Vellucci R, Sarzi-Puttini P, et al. Barriers to pain management: focus on opioid therapy. Clin Drug Investig 2012;32(Suppl. 1):11e9. [93] Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2012;1:CD008921. [94] Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991; 13:383e95. [95] Boers M, Verhoeven AC, Markusse HM, et al. Randomized comparison of combined step-down prednisolone, methotrexate, and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309e18. [96] Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology 2012;51(Suppl. 5):v22e30. *[97] Ramiro S, Radner H, van der Heijde D, et al. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011;10:CD008886. [98] Richards BL, Whittle SL, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2011;11:CD008920. [99] Knittle K, Maes S, de Gucht V. Psychological interventions for rheumatoid arthritis: examining the role of selfregulation with a systematic review and meta-analysis of randomized controlled trials. Arthritis Care Res 2010;62: 1460e72. [100] Baillet A, Vaillant M, Guinot M, et al. Efficacy of resistance exercises in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2012;51:519e27. [101] John H, Hale ED, Treharne GJ, et al. A randomized controlled trial of a cognitive behavioural patient education intervention vs a traditional information leaflet to address the cardiovascular aspects of rheumatoid disease. Rheumatology (Oxford) 2013;52:81e90. [102] Clarke H, Woodhouse LJ, Kennedy D, et al. Strategies aimed at preventing chronic post-surgical pain: comprehensive perioperative pain management after total joint replacement surgery. Physiother Can 2011;63:289e304. [103] Calder JD, Ashwood N, Hollingdale JP. Survivorship analysis of the “Performance” total knee replacement e 7-year follow-up. Int Orthop 1999;23:100e3. [104] Goodman SM, Ramsden-Stein DN, Huang WT, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol 2014;41(9):1774e80. [105] Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896e904. [106] Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new? Curr Rheumatol Rep 2012;14:422e7. *[107] Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol 2011;25:285e97. [108] Sarzi-Puttini P, Atzeni F, Salaffi F. Pain in rheumatic diseases: how relevant is it? Reumatismo 2014;66:1e3. *[109] Sarzi-Puttini P, Atzeni F. Fibromyalgia: a never-ending story of central and peripheral pain mechanisms. Arthritis Rheumatol 2014;66:1687e8.

Please cite this article in press as: Atzeni F, et al., Pain in systemic inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2015), http://dx.doi.org/10.1016/j.berh.2015.04.016